Prostate Cancer

Oncogene Identification Provides Basis for Improved Diagnostics

Published in Gene Therapy Weekly, August 7th, 1995

Doors open for accurate diagnostics and potential therapeutics with the discovery of human prostatic carcinoma oncogene PTI-1.

Current methods for detecting early prostate cancer lack sensitivity and specificity. Physical exams might easily miss small or centrally located tumors; serum prostate-specific antigen (PSA) determination is not specific to malignant prostate disease; and tissue biopsy may lead to erroneous benign diagnosis through sampling error. Current techniques for early prediction/detection of therapeutic relapse are unsatisfactory as they require fairly bulky tumor regrowth before discovery.

Ruoquian Shen et al. cloned and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-08-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry